



# PREVENTING FUNGAL INFECTION IMPROVING QUALITY OF LIFE

## SAFE AND EFFECTIVE PROPHYLACTIC TREATMENT FOR FUNGAL INFECTION IS AN UNMET CLINICAL NEED

**30% mortality rate**

*Among infected patients*

**\$3.5B medical spend**

*Fungal infection treatment*






**\$1.2B  
ADDRESSABLE  
MARKET**

Immunocompromised patients are at the **highest risk** of infection

Current therapeutics cause **liver toxicity** and lead to **microbial resistance**

Based on a **native peptide** which prevents fungal infections with **specificity**



- **Native peptide** inhibits growth of infectious fungi *in vitro* AND *in vivo*
- **Native peptide** maintains commensal fungi

## WE ARE DEVELOPING ANTI-FUNGAL PEPTIDES THAT ARE SAFE AND EFFECTIVE FOR PROPHYLACTIC USE IN IMMUNOCOMPROMISED PATIENTS

Well-Tolerated

Non-Toxic Over Extended Periods

Preserves the Healthy Microbiome

Avoids Microbial Resistance

### Development Milestones

- Completed ***in vitro*** and ***in vivo*** validation of the **native peptide**
- Completed bioengineering of **9 lead AVpeptides**; performing validation with proof of concept capital (Innovation Fund Award, 17')
- **Full patent filed** in May 2018; licensing **intellectual property** from the University of Chicago
- Actively seeking **development partners** and **seed funding** to pursue preclinical testing and IND-enabling studies

### Our Leadership Team



**Dr. Eugene B Chang,**  
MD  
Co-founder & Chief Medical Officer



**Dr. Joseph F Pierre,**  
PhD  
Co-founder & Chief Scientific Officer



**Dr. Katharine Harris,**  
PhD  
Co-founder & Infectious Disease Specialist



**Dr. Judy Prasad,**  
PhD  
Business Lead

Over **50 years** of combined experience in microbiome research

For more information, contact [jprasad@uchicago.edu](mailto:jprasad@uchicago.edu)